The quest for targeted therapy in fragile X syndrome

Area of Science:

• Neuroscience
• Genetics
• Developmental Disorders

Background:

• Fragile X syndrome (FXS) is a leading genetic cause of intellectual disability and autism spectrum disorders.
• Current understanding of FXS neuronal pathway disruptions offers potential therapeutic targets.
• Despite preclinical success, translating FXS mouse model findings to human treatments has proven challenging.

Purpose of the Study:

• To analyze the reasons behind the translational gap between FXS preclinical studies and clinical trials.
• To highlight the complexities of FXS molecular pathology and therapeutic strategies.
• To propose directions for future FXS research and drug development.

Main Methods:

• Review of preclinical studies and clinical trial outcomes for FXS therapies.
• Analysis of factors contributing to variability and lack of success in FXS research.
• Exploration of the molecular complexity of FXS and potential multi-target therapeutic approaches.

Main Results:

• Many FXS phenotypes improved in mouse models, but clinical translation has been largely unsuccessful.
• Complicating factors include mouse strain variability, inter-laboratory differences, publication bias, and inadequate outcome measures.
• The complexity of FXS molecular imbalances, requiring simultaneous targeting of multiple pathways and cellular compartments, is a critical, underexplored factor.

Conclusions:

• Current therapeutic strategies for FXS may be insufficient due to the disease's complex molecular pathology.
• Future research should focus on well-designed animal studies that account for molecular complexity and explore multi-target approaches.
• Developing effective FXS therapies necessitates a deeper understanding and simultaneous targeting of disturbed pathways and cellular compartments.